<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04266418</url>
  </required_header>
  <id_info>
    <org_study_id>201911062RSA</org_study_id>
    <nct_id>NCT04266418</nct_id>
  </id_info>
  <brief_title>The Evaluation of Banana Flower Stamens Extract on Prevention of Benign Prostatic Hyperplasia in Adults</brief_title>
  <official_title>The Evaluation of Banana Flower Stamens Extract on Prevention of Benign Prostatic Hyperplasia in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the evaluation of banana flower stamens extract on prevention of benign prostatic
      hyperplasia in adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind and randomized study. Subjects are informed to consume the samples
      every day for 2 months. The clinical diagnosis item of benign prostatic hyperplasia (BPH) is
      evaluated by the doctor. The questionnaires are collected at every visit of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Change from baseline IPSS at 4 weeks and 8 weeks</time_frame>
    <description>To measure the severity of lower urinary tract symptoms. Each item is scored 0-5, yielding a total between 0-35.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Prostate volume</measure>
    <time_frame>Change from baseline prostate volume at 8 weeks</time_frame>
    <description>To measure the volume of prostate measured by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International index of erectile function (IIEF)</measure>
    <time_frame>Change from baseline IIEF at 4 weeks and 8 weeks</time_frame>
    <description>To evaluate male sexual function over the past 6 months. Each item is scored 1-5, yielding a total between 5-25.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-voiding residual urine</measure>
    <time_frame>Change from baseline post-voiding residual urine at 8 weeks</time_frame>
    <description>To measure and compare the amount of urine left in the bladder after urination before and after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate</measure>
    <time_frame>Change from baseline maximum flow rate at 8 weeks</time_frame>
    <description>To determine peak urine flow rate and average urine flow rate (mL/sec).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>consume 1 sachet per day for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Banana flower stamens extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>consume 1 sachet per day for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>consume 1 sachet per day for 2 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Banana flower stamens extract</intervention_name>
    <description>consume 1 sachet per day for 2 months</description>
    <arm_group_label>Banana flower stamens extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male aged 40-80 years old

          2. 7 ≤ IPSS score &lt;19

          3. The subject did not take α-blocker or anticholinergic agents in the last 8 weeks. The
             subject did not take 5α-reductase inhibitor or androgen suppression agents in the last
             16 weeks (depending on medical history).

          4. The subject isn't diagnosed with cancer

          5. The subject is able to read and finish the information on the questionnaire.

          6. The subject must read and sign the informed consent form after the study has been
             fully explained.

        Exclusion criteria:

          1. The subject has a history of epilepsy or convulsions, liver and kidney disease,
             cancer, endocrine disease, mental illness, alcohol or drug abuse, and other major
             organic diseases (depending on medical history).

          2. The lower urinary tract urination symptoms of the subject are not related to prostatic
             hypertrophy (depending on medical history).

          3. Residual urine volume &gt; 250 mL (depending on medical history)

          4. Subjects have had pelvic radiation therapy or pelvic surgery (including prostate or
             bladder surgery, but those who only have had a prostate slice can participate in the
             trial).

          5. Subjects have taken sexual hormone preparations including LHRH agonists,
             anti-androgens, feminine, or Penta-reductase inhibitors (Proscar and Avodart) 16 weeks
             prior to the trial.

          6. Subjects have participated in other clinical trials 12 weeks prior to the trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuo-How Huang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyr-Chyr Chen</last_name>
    <phone>(02) 23123456</phone>
    <email>scchen@ntu.edu.tw</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 10, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

